Clinical Trials Logo

Relapsed Osteosarcoma clinical trials

View clinical trials related to Relapsed Osteosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04661852 Completed - Clinical trials for Refractory Osteosarcoma

Cabozantinib With Topotecan-Cyclophosphamide

Start date: December 23, 2020
Phase: Phase 1
Study type: Interventional

This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

NCT ID: NCT01804374 Completed - Clinical trials for Metastatic Osteosarcoma

Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma

SERIO
Start date: June 2011
Phase: Phase 2
Study type: Interventional

This is a trial for patients affected by metastatic or relapsed osteosarcoma which progressed after first or further line treatments. In this trial, all patients will be treated until progression or unacceptable toxicity with sorafenib and everolimus. The treatment with sorafenib and everolimus aimed to obtain a 50% rate of patients free from further progression of the disease after 6 months from study entry.